Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITCINYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITCIIntra-Cellular Therapies$131.25+0.0%$122.06$63.30▼$131.37$13.96B0.691.32 million shs2.68 million shsJNJJohnson & Johnson$162.93-1.8%$154.23$140.68▼$169.99$392.27B0.477.09 million shs8.01 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITCIIntra-Cellular Therapies+0.01%+0.05%+3.25%+57.37%+103.90%JNJJohnson & Johnson-1.77%-1.39%+5.65%+11.42%+0.12%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationITCIIntra-Cellular Therapies3.6053 of 5 stars2.23.00.04.52.91.70.6JNJJohnson & Johnson4.4444 of 5 stars2.33.04.23.92.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITCIIntra-Cellular Therapies 2.47Hold$106.08-19.18% DownsideJNJJohnson & Johnson 2.56Moderate Buy$171.335.16% UpsideCurrent Analyst Ratings BreakdownLatest JNJ and ITCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/10/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/5/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$159.00 ➝ $171.002/24/2025ITCIIntra-Cellular TherapiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$140.00 ➝ $132.002/21/2025ITCIIntra-Cellular TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/19/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.002/3/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$162.00 ➝ $166.001/31/2025ITCIIntra-Cellular TherapiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$119.00 ➝ $132.001/28/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$159.00 ➝ $166.001/24/2025JNJJohnson & JohnsonArgusSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/23/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.001/23/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$175.00 ➝ $163.00(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITCIIntra-Cellular Therapies$680.50M20.51N/AN/A$6.15 per share21.34JNJJohnson & Johnson$88.82B4.42$13.39 per share12.17$29.69 per share5.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITCIIntra-Cellular Therapies-$139.67M-$0.73N/A690.79N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)JNJJohnson & Johnson$14.07B$6.6524.5014.722.5618.20%34.24%13.63%4/15/2025 (Estimated)Latest JNJ and ITCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million1/22/2025Q4 2024JNJJohnson & Johnson$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/AJNJJohnson & Johnson$4.963.04%+5.43%74.59%63 YearsLatest JNJ and ITCI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/2/2025JNJJohnson & Johnsonquarterly$1.243.43%2/18/20252/18/20253/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITCIIntra-Cellular TherapiesN/A7.667.51JNJJohnson & Johnson0.431.110.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITCIIntra-Cellular Therapies92.33%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipITCIIntra-Cellular Therapies2.60%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITCIIntra-Cellular Therapies560106.33 million103.56 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableJNJ and ITCI HeadlinesRecent News About These CompaniesJohnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials in Moderate-to-Severe Plaque Psoriasis, Ulcerative ColitisMarch 12 at 5:10 PM | appliedclinicaltrialsonline.comJohnson & Johnson MedTech showcases new orthopedic offerings at AAOSMarch 12 at 5:10 PM | massdevice.comForget About a Market Correction: Baby Boomers Should Buy These 3 Bulletproof Dividend Stocks NowMarch 12 at 3:49 PM | 247wallst.comJohnson & Johnson (NYSE:JNJ) Trading Down 1.7% - Should You Sell?March 12 at 3:11 PM | marketbeat.comWhy Johnson & Johnson (JNJ) is the Best Pharma Stock to Buy According to Hedge FundsMarch 12 at 2:57 PM | insidermonkey.comSix Dean Omar Branham Shirley Attorneys Honored for Representation of PlaintiffsMarch 12 at 1:41 PM | businesswire.comLilly, J&J boosted spending on executive security after UnitedHealth shootingMarch 12 at 1:16 PM | reuters.comChatGPT picks 3 safe haven stocks to buy for 2025March 12 at 12:16 PM | finbold.comJohnson & Johnson MedTech wins FDA nod for enhanced robotic-assisted bronchoscopyMarch 12 at 12:10 PM | massdevice.comJohnson & Johnson (JNJ): Among Dobermans of the Dow to BuyMarch 12 at 12:10 PM | msn.comJohnson & Johnson (NYSE:JNJ) Trading Up 1.5% - Here's WhyMarch 12 at 9:13 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Avantax Advisory Services Inc.March 12 at 7:51 AM | marketbeat.comSecurian Asset Management Inc. Lowers Stake in Johnson & Johnson (NYSE:JNJ)March 12 at 7:34 AM | marketbeat.comGreat Lakes Advisors LLC Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)March 12 at 7:24 AM | marketbeat.comHopwood Financial Services Inc. Invests $759,000 in Johnson & Johnson (NYSE:JNJ)March 12 at 7:09 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Saturna Capital CorpMarch 12 at 6:30 AM | marketbeat.comWindle Wealth LLC Has $6.60 Million Stake in Johnson & Johnson (NYSE:JNJ)March 12 at 6:21 AM | marketbeat.comNatural Investments LLC Takes $986,000 Position in Johnson & Johnson (NYSE:JNJ)March 12 at 5:48 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by River Road Asset Management LLCMarch 12 at 5:33 AM | marketbeat.comRaymond James Financial Inc. Takes $1.34 Billion Position in Johnson & Johnson (NYSE:JNJ)March 12 at 3:51 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Earns "Neutral" Rating from GuggenheimMarch 12 at 3:09 AM | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNJ and ITCI Company DescriptionsIntra-Cellular Therapies NASDAQ:ITCI$131.25 +0.01 (+0.01%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$131.25 0.00 (0.00%) As of 03/12/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Johnson & Johnson NYSE:JNJ$162.93 -2.93 (-1.77%) Closing price 03/12/2025 03:59 PM EasternExtended Trading$163.10 +0.17 (+0.10%) As of 03/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
